指南与共识母胎医学产科

基于国际专家德尔菲共识的胎儿和新生儿溶血性疾病监测与管理

Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus.
指南 / 共识 · Am J Obstet Gynecol · 2024-11-14

该研究旨在制定胎儿和新生儿溶血性疾病产前及产后管理的结构化专家临床指导。研究采用德尔菲法,由来自25个国家、6大洲的107位专家参与,首轮完成107人,后续轮次完成100人(93.5%)。共识阈值设定为≥70%同意率,在产前检查、产前监测与管理、宫内输血、分娩及产后管理五个领域形成推荐。

要点

  • 75.3%专家同意使用cfDNA确定胎儿抗原状态,尤其针对RhD、Kell和Rhc抗原。
  • 非Kell抗原需胎儿超声监测的临界滴度阈值为≥16。
  • 70.0%专家同意对既往24周前接受宫内输血或发生HDFN相关胎儿/新生儿死亡的孕妇使用母体IVIg。

核心结论

  • 该国际专家德尔菲共识形成了胎儿和新生儿溶血性疾病产前及产后管理的结构化临床指导。

研究设计与样本

  • 采用德尔菲法,由胎儿医学、新生儿科和血液学国际专家小组参与,专家基于专业知识、相关发表和所属机构遴选,共识阈值预设为≥70%同意率。
  • 首轮107位专家代表25个国家、6大洲完成,后续轮次100位(93.5%)完成。
  • 研究领域包括:(i)产前检查,(ii)产前监测与管理,(iii)宫内输血(IUT),(iv)分娩,(v)产后管理。

主要发现

  • 75.3%专家同意使用cfDNA确定胎儿抗原状态,尤其针对RhD、Kell和Rhc抗原。
  • 非Kell抗原需胎儿超声监测的临界滴度阈值为≥16。
  • 70.0%专家同意对既往24周前接受IUT或发生HDFN相关胎儿/新生儿死亡的孕妇使用母体IVIg。
  • IUT最小孕周为16至18周,最大孕周为350/7至356/7周。
  • 产后管理共识:出院前检查贫血指标(92.0%同意),IUT者出院1周内复查(84.0%同意),换血 centralized 于经验充足的医院(96.0%同意),出院后考虑输血的血红蛋白阈值为7 g/dL(92.0%同意),新生儿监测至2至3月龄(96.0%同意)。

关键数值与推荐

  • cfDNA用于确定胎儿抗原状态(尤其RhD、Kell和Rhc抗原)获得75.3%同意。
  • 非Kell抗原的临界滴度阈值为≥16,需胎儿超声监测。
  • 母体IVIg用于既往24周前IUT或HDFN相关胎儿/新生儿死亡的孕妇,获得70.0%同意。
  • IUT孕周范围为16至18周至350/7至356/7周。
  • 产后管理推荐:出院前检查贫血指标(92.0%),IUT者出院1周内复查(84.0%),换血 centralized 于经验充足医院(96.0%),出院后输血血红蛋白阈值为7 g/dL(92.0%),监测至2至3月龄(96.0%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The study aimed to develop structured, expert-based clinical guidance on the prenatal and postnatal management of hemolytic disease of the fetus and newborn. A Delphi procedure was conducted among an international panel of experts in fetal medicine, neonatology, and hematology. Experts were selected based on their expertise, relevant publications, and affiliations. The domains were (i) prenatal workup, (ii) prenatal monitoring and management, (iii) intrauterine transfusion (IUT), (iv) delivery, and (v) postnatal management. The predefined cut-off for consensus was ≥70% agreement. One hundred-seven experts representing 25 countries across 6 continents completed the first round, and 100 (93.5%) completed the subsequent rounds. 75.3% agreed on using cfDNA to determine fetal antigen status, particularly for RhD, Kell, and Rhc antigens. The critical titer, requiring fetal monitoring via ultrasound, is considered when the threshold of ≥16 is for non-Kell antigens. 70.0% agreed on the use of maternal IVIg in pregnancies with prior IUT <24 weeks or fetal/neonatal death due to HDFN. The minimum GA for IUT is 16 to 18 weeks, and the maximum is 350/7 to 356/7 weeks. Postnatal management consensus was reached for the following: anemia labs should be investigated in the affected neonates before hospital discharge (92.0% agreement), and if they received IUT, the labs should be repeated within 1 week of discharge (84.0% agreement). 96.0% agreed that exchange transfusions should be centralized in hospitals with sufficient exposure and experience, and 92.0% agreed that the hemoglobin cut-off level to consider transfusion following hospital discharge is 7 g/dL, and the newborns need to be monitored until 2 to 3 months of age (96.0% agreement).

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Mustafa HJ, Sambatur EV, Shamshirsaz AA, et al. Monitoring and management of hemolytic disease of the fetus and newborn based on an international expert Delphi consensus. Am J Obstet Gynecol. 2024. PMID: 39547350. doi:10.1016/j.ajog.2024.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。